West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$316.50 USD
+8.57 (2.78%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $316.68 +0.18 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$316.50 USD
+8.57 (2.78%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $316.68 +0.18 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Zacks News
LH vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. WST: Which Stock Is the Better Value Option?
Thermo Fisher (TMO) Releases New Update for Omicron Detection
by Zacks Equity Research
Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.
Is West Pharmaceutical (WST) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
West Pharmaceutical (WST) possesses solid growth attributes, which could help it handily outperform the market.
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.
Bruker (BRKR) Introduces JPK NanoWizard V for AFM Research
by Zacks Equity Research
Bruker's (BRKR) newly-introduced JPK NanoWizard V is expected to significantly contribute to life science atomic force microscopy investigations.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Thermo Fisher Scientific (TMO) and West Pharmaceutical Services (WST) have performed compared to their sector so far this year.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Boston Scientific (BSX) New Buyouts Aid Amid COVID Resurgence
by Zacks Equity Research
Boston Scientific's (BSX) new acquisitions like Preventice, Farapulse and Lumenis Surgical, which closed in March, August and September of 2021, respectively, are contributing to its inorganic growth.
Alcon (ALC) on Track With Successful Global PRECISION1 Rollout
by Zacks Equity Research
Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).
CVS Health (CVS) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Robust performance by the Pharmacy Services and Health Care Benefits arms is driving the top line for CVS Health (CVS).
Hologic (HOLX) Reports New Findings on Breast Cancer Index
by Zacks Equity Research
Hologic's (HOLX) latest data on Breast Cancer Index demonstrates its effectiveness in predicting net benefit from extended endocrine therapy.
Here's Why You Should Hold on to Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.
Thermo Fisher (TMO) Completes Acquisition of Leading CRO
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of PPD is likely to bolster its Laboratory Products and Services arm.
LH vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. WST: Which Stock Is the Better Value Option?
3 Reasons Why West Pharmaceutical (WST) Is a Great Growth Stock
by Zacks Equity Research
West Pharmaceutical (WST) could produce exceptional returns because of its solid growth attributes.
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Thermo Fisher Scientific (TMO) and West Pharmaceutical Services (WST) have performed compared to their sector so far this year.
4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic
by Riya Anand
Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.
Is West Pharmaceutical Services (WST) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider West Pharmaceutical Services (WST).
DaVita (DVA) Study Favors mRNA Vaccines for Dialysis Patients
by Zacks Equity Research
DaVita's (DVA) latest study indicates favorable outcomes for ESKD patients regarding the COVID-19 vaccines.
Here's Why You Should Invest In Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.
QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.
3 Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and its focus on growth strategies.